Introduction
The Ki67 antigen, which encodes two protein isoforms with molecular weights of 345 and 395 kDa, was originally identified by Scholzer and Gerdes in the early 1980s (1) . The Ki67 protein has a half-life of only ~1-1.5 h. It is present during all active phases of the cell cycle (G1, S, G2 and M), but is absent in resting cells (G0) (2, 3) . In later phases of mitosis (during anaphase and telophase), a sharp decrease in Ki67 levels occurs (4) . Expression of the Ki67 protein (pKi67) is associated with the proliferative activity of intrinsic cell populations in malignant tumors, allowing it to be used as a marker of tumor aggressiveness (5, 6) . The prognostic value of pKi67 has been investigated in a number of studies with its potential as a reliable marker having been shown in cancers of the breast, soft tissue, lung, prostate, cervix and central nervous system (7) (8) (9) (10) (11) .
Current classification schemes may require revision where biological behavior and prognostic significance of these tumors is concerned, as an increasing number of studies have suggested that Ki67 may be an important factor in cancer grading and prognostic evaluation. It has been shown that Ki67 immunohistochemical (IHC) staining is an effective method of assessing the prognosis in a number of tumor types (12, 13) .
Although pKi67 is a key marker associated with proliferating cancer cells and a poor prognosis, its full potential in increasing proliferation has not been evaluated. In syngeneic animal models with subcutaneous or orthotopic bladder cancer, prostate cancer or renal cell carcinoma, antisense oligonucleotides induced tumor growth inhibition (14, 15) , potentially through the inhibition of Ki-67, indicating the involvement of Ki67 in tumor cell proliferation.
This review provides an update on the current knowledge of Ki67 and the evidence regarding the prognostic and predic-
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tive role of this marker (Fig. 1) . It also discusses the laboratory techniques used to determine Ki67 levels.
Characteristics of pKi67
The Ki67 antigen was originally identified in the 1980s, as a proliferation-associated nuclear antigen, which is only detected in dividing cells (G1-, S-, G2-and M-phase) and not in quiescent cells (G0 phase) (16) . Ki67 levels are low in the G1 and S phases and peak early in mitosis. In later phases of mitosis, a sharp decrease in Ki67 levels occurs (17 (18) (19) (20) . The quantity of pKi67 present at any time during the cell cycle is regulated by a precise balance between synthesis and degradation, as indicated by its short half life of 1-1.5 h (20, 21) . Ki67 protein expression coincides with the transit of cells through mitosis and undergoes phosphorylation and dephosphorylation during mitosis in vivo, rendering it susceptible to protease degradation. Furthermore, its structure indicates that its expression is regulated by proteolytic pathways, such as those controlled by the key regulatory complex cyclin B/cyclin-dependent kinase 2 (1, 22) . pKi67 is known to share structural similarities (including a so-called fork head-associated domain) with other proteins, such as DUN1 and RAD, which are involved in cell cycle regulation (23).
The characterization of the Ki67 promoter region is essential for understanding gene transcription, and it is therefore important to investigate this in order to develop targeted interventions aimed at modulating gene expression (24). In a previous study, deletion analysis and a dual luciferase reporter assay were used to locate the Ki-67 core promoter from -223 to +12 nt relative to the transcriptional initiation site, which is a TATA less, GC rich region comprised of several putative Sp1 binding sites. It was demonstrated that the region from -223 to +12 nt could drive the transcription of the Ki-67 gene, and that the Sp1 binding site is essential for the transcriptional regulation of the Ki-67 gene. (25). An electrophoretic mobility shift assay revealed three Sp1-binding sites in the Ki67 promoter that are essential for its basal transcriptional activity.
It was found that expression of p53 is correlated with that of Ki67 in several types of cancer, including oral squamous cell cancer and breast cancer (26). How p53 may affect Ki67 gene expression is not yet clear. As there are three Sp1-binding sites in the Ki67 promoter and as p53 represses the transcription of genes at Sp1-binding sites of promoters (20, 26, 27) , it is likely that p53 inhibits Ki67 promoter activity via p53-and Sp1-dependent pathways. It is hypothesized that there are at least two transcriptional regulatory mechanisms. One is that the p53-binding motifs affect the transcriptional repression of the Ki67 promoter. The other is a possible interaction between p53 and Sp1 at Sp1-binding sites on the Ki67 promoter.
Scoring and methodology
Scoring systems are based on the percentage of tumor cells stained by an antibody. In order to assess the methodology of a study, a publication is scored using The World Health Organization's classification system (28). The score is determined by various aspects of methodology, which are grouped into three main categories: The scientific design, the description of the laboratory methods used to identify the presence of pKi67, DNA/RNA or antibodies against Ki67 (29,30), and some clinical reports that have used the techniques for Ki67 detection (31-34). Briefly, an automated bright-field microscope and software are used to detect and classify. After the Ki67-stained slide has been scanned at x5 magnification, a trained clinical laboratory scientist, who is blinded to the histological diagnoses and patient survival data, randomly selects at least eight fields representative of the range of Ki67 immunostaining in the previously encircled tumor for evaluation with an automated bright-field microscope at x20 (35). The percentage of Ki-67-positive tumor nuclei (Ki-67 index) was quantitated for each case using the Ariol® SL-50 Image Analyzer and imaging software (Genetix Corp, Boston, MA, USA)
Multiple clinical laboratories have reported the successful use of Ki67 as a diagnostic tool (36-39). Expression of Ki67, as evaluated by immunostaining has become the gold standard, with a cutoff level of between 10 and 14% positively-stained cells defined as high risk in terms of prognosis (40-42). The St Gallen Consensus in 2009 considered the Ki-67 labelling index important for selecting the addition of chemotherapy to endocrine therapy in hormone receptor-positive breast cancers. In addition, tumors may be classified as low, intermediate, and highly proliferating, according to the Ki-67 labelling index of ≤15%, 16%-30%, and >30%, respectively (43). Tissue microarray technology has become increasingly important over the past decade. There are concerns with the scoring reliability of tissue microarrays due to tumor heterogeneity. To overcome this issue, certain experts have used multiple cores when conducting this analysis (44,45). However, a number of pathologists have expressed the view that using a manual counting procedure will obtain a more reliable score, which may lead to differences in interpretation between examiners with consequent variability in diagnoses (46). By contrast, reverse transcription-quantitative polymerase chain reaction assays, with convenient quantification of target transcripts, result in objective and continuous data variables.
Nowadays, formalin-fixed paraffin-embedded tissue samples are routinely used for gene expression analysis, which can aid in overcoming technical difficulties (47) (48) (49) (50) . The use of formalin-fixed, paraffin-embedded (FFPE) tissue overcomes the most prominent issues related to research on relatively rare diseases: limited sample size, availability of control tissue, and time frame.
FFPE samples are easy to handle and store and are suitable for diagnostic histology, immunohistochemistry, and in situ hybridization. Therefore, this sample type is almost always available for diseases in which treatment involves surgery to remove parts of or almost the entire affected organ. Furthermore, invaluable clinical information and follow-up data are often accessible in conjunction with FFPE samples (3). Lastly, the tissue is usually available in amounts adequate for use in GEM studies and obtained biologically relevant and disease-specific, significant genes; cancer-related genes.
pKi67 as a diagnostic tool
Ki67 is frequently used as an indicator of cell proliferation (51, 52) . A number of diagnostic applications for pKi67 have been described, where Ki67 was significantly more highly expressed in malignant than in normal tissues (53, 54) . pKi67 also tended to increase with decreasing tissue differentiation, and it was correlated with the presence of occult metastasis and the clinical stage of tumors (55) (56) (57) (58) . Proliferative activity in tumors can be determined by mitotic counting, flow-cytometric determination of synthesis-phase fraction and immunohistochemistry using antibodies reactive against various proliferating cellular antigens. The Ki67/MIB-1 monoclonal antibody is commonly used, and is reactive against the nuclear antigen Ki67 that is expressed during cell cycle phases G1, S, G2 and M, but is not found during G0 (27,59,60). The percentage of immunoreactive tumor cell nuclei is expressed as a labeling index (LI). Studies thus far have all shown a positive correlation between Ki67/MIB-1 LI and tumor grade in human malignancy. Due to the limitations of routine histological examination of tumor tissue in predicting tumor behavior, Ki67/MIB-1 immunostaining has been introduced for its potential to improve the information provided by the grading system (27,61). Its presence in a variety of tumors indicates that it may be possible to use Ki67 in routine grading of cancer (62) (63) (64) (65) . Judicious use of this proliferation marker in combination with established histopathological features of malignancy may serve as a more reliable indicator of the likelihood of tumor recurrence (66) .
The data on Ki67 as a diagnostic marker is scarce and based on varying laboratory and statistical methods. Cancer has a complex pathogenesis and reliable early diagnosis is difficult. Symptoms usually do not appear until the disease has progressed to an advanced stage. Therefore, further research into diagnostic and prognostic markers may aid early diagnosis. Notably, the expression of Ki67 reflects the tumor proliferation rate and correlates with initiation, progression, metastasis and prognosis of a number of types of tumors (18, (67) (68) (69) (70) (71) (72) . Certain regulators of these processes, such as Smac (73) (74) (75) (76) , minichromosome maintenance 7 (77), p53 (10, (78) (79) (80) , Bcl-2 (81), proliferating cell nuclear antigen (PCNA) (75) and CD105 (82) have been investigated. In a number of studies, Ki67 appeared to be closely correlated with pancreatic tumor severity as well as with expression of Smac and thus may be useful as a diagnostic and prognostic marker or, in conjunction with Smac, as an indicator of treatment efficacy (73) (74) (75) . In a further study, Chen et al (83) reported that utilizing Ki67 LI and vascular endothelial growth factor scoring is useful to effectively and accurately predict outcomes and optimize personal therapy in judging the outcomes of non-muscle invasive bladder cancer This novel molecular grading system could enhance the efficiency of the conventional system.
Colorectal carcinoma is the fourth leading cause of cancer-related mortality worldwide (84) . It has been demonstrated that the Ki67 LI was higher in Dukes' stage B than in Dukes' stage C carcinoma. They concluded that the positive rate of Ki-67 antibody in poorly differentiated adenocarcinoma and mucinous carcinomas was significantly lower than in well differentiated and moderately differentiated adenocarcinomas, suggesting that proliferative activity is low in cancers with poor differentiation. On the other hand, it has been demonstrated that the Ki-67 LI is high in well to moderately differentiated, non-mucinous adenocarcinomas in an early Dukes' stage (A or B) as compared with that in poorly differentiated, mucinous adenocarcinomas or signet-ring cell colorectal carcinomas in an advanced Dukes' stage (C). MIB-1 is a monoclonal antibody that recognizes a fixation resistant epitope of the Ki67 antigen and it is used to estimate the proliferative fraction of neoplasia (85) . Using MIB-1, it was observed that Ki67 LI was high in Grade I and Grade II as compared with the Grade III carcinomas.
The Ki67 index is a diagnostic and prognostic aid in several fields of pathology and an established predictive tool in others (37,86-90). However, existing Ki67 index estimations are time-consuming and cumbersome, and may be subject to inter-observer variability (90) (91) (92) (93) . To improve the accuracy of the Ki67 index, current research recommends the use of an IHC cocktail, which detects Ki67 and the melanocytic marker, melanoma antigen recognized by T cells (MART1) (94) . In melanocytic pathology, current research favors using Ki67/MART1 double stains to accurately distinguish Ki67-positive melanocytic cells from other proliferating Ki67-positive cells, including lymphocytes, stromal cells and epithelial cells (95, 96) . The usability and cost benefit of automated MART1-verified Ki67 indices in routine settings require investigation in a prospective study with a consecutive inclusion of specimens. When predicting a clinical outcome for the individual patient, automated MART1-verified Ki67 indices may be more reliable as a result of a reduction in false positive results with this assay.
pKi67 as a prognostic tool
It is known that Ki67 is expressed in all cell-cycle phases outside of the resting phase G0. Academics recommend its use as a prognostic marker over mitotic rate (97) (98) (99) (100) . A number of studies have shown a correlation between proliferative markers and tumor grade (13, 82, 101) . Studies have also suggested a predictive role for pKi67, in that an individual patient may be treated with a specific regimen based on the degree of pKi67 expression (78) . While a prognostic biomarker indicates the likely course of the disease in an untreated individual, a predictive biomarker identifies subpopulations of patients who are most likely to respond to a given therapy. The results of one study indicated that the Ki67 labeling index is an independent prognostic factor for survival rate, including all stage and grade categories (102) . Studies demonstrated a correlation between the ratio of Ki67-positive malignant cells and patient survival (103, 104) . Vogt and Klapper (105) showed that the Ki67 index was associated with prognosis in specimens from patients with primary and relapsed mantle cell lymphoma in the large cohort, which was included in the first of a number of studies on MCLs. The pretherapeutic assessment of Ki67 expression is becoming more important in the evaluation of tumor aggressiveness and the selection of adequate treatment.
In a number of tumors there appears to be a degree of correlation between pKi67 expression and patient survival, e.g. cervical and uterine cancer, non-Hodgkin's lymphoma and large bowel cancer (106, 107) . Indeed, Kimura et al (6) found that cases of colorectal carcinoma showing a high pKi67 expression at the site of deepest invasion had a worse prognosis. These findings may be the result of the marked heterogeneity of pKi67 expression in carcinomas. Numerous studies have similarly confirmed the utility of the Ki67 proliferation index as a prognostic indicator in cancer, as it shows a correlation with primary tumor size, lymphatic invasion, metastases, tumor proliferation activity measured by DNA flow cytometry and shorter patient survival times.
Mucosal malignant melanoma (MMM) of the sinonasal tract accounts for 1% of all mucosal melanomas and 3-4% of malignant neoplasms of the sinonasal tract (108) . Intense immunohistochemical staining for Ki67 is correlated with a poor prognosis in various malignancies (95, 109, 110) . One study reported that scores of ≤40% for Ki67 and ≤80% for PCNA were correlated with good prognosis in anorectal malignant melanoma (74, 111) . Another study showed that scores of ≤20% for Ki67 and ≤35% for PCNA were correlated with a good prognosis in cutaneous malignant melanoma (84, 112) . These studies showed that Ki67 is negatively correlated with a more favorable prognosis, which indicates that the Ki67 antigen may be useful as a diagnostic and prognostic factor for MMM.
Ki-67 as a potential therapeutic target for cancer therapy
Ki-67 is a sensitive protein associated with cell proliferation. Owing to high cell proliferation, frequently associated with the Ki-67 protein labeling index, Ki67 may be a promising factor for targeted molecular therapies.
Antisense oligodeoxynucleotides (ASOs) have been studied as specific tools for treating tumors (14, 113) . In syngeneic animal models, Ki-67-ASOs markedly inhibit tumour growth (114, 115) . However, there are several factors that effect their application, including nuclease degradation (116) . In order to improve the characteristics of ASOs, the development of their derivatives requires promotion, particularly that of peptide nucleic acids (PNAs) (117) . PNAs are a DNA mimic that can target DNA and RNA with high specifically and affinity (105, 118, 119) . In vitro, anti-K-67 PNAs yielded a stronger inhibitive effect on Ki-67 expression than ASOs, and had greater effects on the proliferation and apoptosis of human renal carcinoma cells (115) .
In recent years a new technique, known as RNA interference (RNAi), has been developed, which suppresses gene expression mediated by siRNAs (120) . siRNA-inhibition of Ki-67 expression has been shown to lead to significant inhibition of proliferation (14, 121) . While synthetic siRNAs can rapidly knock down target genes and achieve similar effects, the result is transient (73) . The most significant obstacles in the use of siRNAs are efficient uptake and long-term stability (122) . To resolve these problems, certain studies have investigated the transfection of plasmid vectors to stably synthesize so-called "short hairpin RNAs" (shRNAs) in host cells, which makes it possible alter native cell processes (123) (124) (125) .
Concurrently, another study constructed a novel oncolytic adenovirus-based shRNA expression system named ZD55, an E1B 55kDa-deficient oncolytic adenovirus that is similar to ONYX-015 (126) , which has the ability to deliver Ki-67-shRNA and the lytic ability of oncolytic adenoviruses. ZD55-Ki67 induces silencing of the Ki-67 gene, allowing for efficient tumor-specific viral replication and inducing the apoptosis of tumor cells in vitro and in nude mice (127) .
Furthermore, the microinjection of antibodies directed against the Ki-67 was shown to result in a decreased rate of cell division (128, 129) . In this technique, the nuclear localization presents a major hurdle, due to the need for intracellular and intranuclear delivery of targeting and therapeutic moieties. Zhang et al (129) used a liposomally encapsulated construct to design photo immunoconjugate-encapsulating liposomes (PICELs). Non-cationic PICELs are particularly useful for the subcellular delivery of mAbs and provide multi-functional constructs for imaging and therapy.
In summary, due to its ubiquitous expression in all proliferating cells and the prognostic value of the Ki-67 index in many cancers, pKi-67 is an potentially attractive therapeutic target in cancer, and strategies that inactivate pKi-67 are a promising anti-proliferative approach, with potentially broad applicability in cancer treatment (14) . Hence, targeting pathways and molecular markers implicated in cancer cell growth is a promising avenue for the development of effective therapies.
Conclusion
As a proliferation marker to measure the growth fraction of cells in human tumors, the expression of Ki67 is strongly associated with cell proliferation and is widely used in routine pathology. pKi67 is well characterized at the molecular level and extensively used as a prognostic and predictive marker in cancer. Based on the studies presented here, Ki67 may be a promising molecular candidate for the diagnosis and treatment of a wide range of malignancies. 
